Corcept Therapeutics (NASDAQ: CORT) reported Q1 EPS of $0.14, $0.05 worse than the analyst estimate of $0.19. Revenue for the quarter came in at $105.7 million versus the consensus estimate of $104.91 million.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.